170809-51-5
170809-51-5
Chemical Structure
Astressin
- CAS No.: 170809-51-5
- Formula:C161H269N49O42
- Molecular Weight:3563.16
SMILES: [C@H](CC1=CN=CN1)(C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@@H]2C(=O)N[C@@H](C)C(=O)N[C@@H](CC3=CN=CN3)C(=O)N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@@H]([C@H](CC)C)C(N)=O)=O)[C@H](CC)C)=O)CCC(O)=O)=O)CCCC)=O)CC(C)C)=O)CCCCN)=O)CCCNC(=N)N)=O)CC(N)=O)=O)CCCCNC(=O)CC2)=O)CCC(N)=O)=O)C)=O)CC(C)C)=O)CCC(N)=O)=O)CCC(O)=O)=O)C)=O)CCCNC(=N)N)=O)C)=O)CCCC)=O)CCC(O)=O)=O)CC(C)C)=O)C(C)C)=O)CCC(O)=O)=O)CCCNC(=N)N)=O)CC(C)C)=O)CC(C)C)=O)NC([C@@H](CC4=CC=CC=C4)N)=O
Biological Activity: Astressin is a potent corticotropin releasing factor (CRF) antagonist.
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Astressin | 98.37% | Astressin is a potent corticotropin releasing factor (CRF) antagonist. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Ro 25-1553 | Ro 25-1553 is a selective VIP2 receptor (VPAC2 receptor) agonist. Ro 25-1553 exhibits bronchodilatory effects on tracheal smooth muscle contractions induced by nerve stimulation or Carbachol (HY-B1208). Ro 25-1553 produces a superimposed effect when combined with Formoterol and Salmeterol (HY-14302). Ro 25-1553 can be used for the study of bronchoconstriction. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
K41498 | 99.66% | K41498 is a highly selective CRF 2 receptor antagonist, with a Ki of 0.66 nM for human CRF2α receptor and a Ki of 0.62 nM for human CRF2β receptor. K41498 inhibits cAMP accumulation in cells expressing CRF2. K41498 antagonizes the hypotensive response induced by systemic administration of urocortin in conscious rats. K41498 undergoes radioiodination without loss of activity and serves for autoradiographic studies of native CRF2 receptors in rat brain and peripheral tissues. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Antisauvagine-30 | 99.74% | Antisauvagine-30 (aSvg-30) is a selective peptide antagonist of the CRF2 receptor, with an IC50 of 1.1 nM for mouse CRF2. Antisauvagine-30 modulates cAMP signaling, gastric emptying, food intake, fear conditioning, anxiety-like behavior, stress responses, corticosterone levels, c-Fos expression, and CRF expression. Antisauvagine-30 is used in studies of anxiety-related disorders. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Astressin 2B | 97.81% | Astressin 2B is a blood-brain barrier-impermeable, highly selective CRFR2 antagonist (rCRFR2, IC50=0.57 nM). Astressin 2B blocks the protective effects mediated by CRFR2, thereby exacerbating indomethacin (HY-14397)-induced hemorrhagic intestinal injury in rats. Astressin 2B reverses the protective effects of Urocortin 1 against intestinal hypermotility, bacterial invasion and upregulation of inflammatory mediators. Astressin 2B also blocks the anxiogenic effect of Urocortin 2 and attenuates stress-induced anxiety-related behaviors. In the Clostridioides difficile toxin A (C. difficile toxin A)-mediated enteritis model, Astressin 2B mimics the phenotype of CRFR2-deficient mice, significantly exacerbating intestinal epithelial damage, edema, neutrophil migration and the expression of multiple proinflammatory cytokines. Astressin 2B is an important tool molecule for investigating the intestinal protective mechanisms of CRFR2. |
||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
GRF (1-29) amide (rat) | 99.80% | GRF (1-29) amide (rat) is a synthetic peptide which can stimulate the growth hormone (GH) secretion. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
CRF(6-33)(human) | 99.61% | CRF(6-33)(human) is a CRF binding protein (CRF-BP) ligand inhibitor. CRF(6-33)(human) competitively binds the CRF-BP but not the post-synaptic CRF receptors. CRF(6-33)(human) has anti-obesity effect. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
[K15,R16,L27]VIP(1-7)/GRF(8-27) | [K15,R16,L27]VIP(1-7)/GRF(8-27), a VIP1 selective agonist, exhibits IC50 values of binding of 2 nM, 1 nM, 30,000 nM for the human VIP1, rat VIP1, rat VIP2 receptors, respectively. VIP: VASOACTIVE Intestinal Polypeptide | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
(D-Phe12,Nle21,38,α-Me-Leu37)-CRF (12-41) (human, rat) | (D-Phe12,Nle21,38,α-Me-Leu37)-CRF (12-41) (human, rat) is a CRF antagonist. (D-Phe12,Nle21,38,α-Me-Leu37)-CRF (12-41) (human, rat) prevents the IL-1a induced Luteinizing hormone (LH) inhibition. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Acetyl-(D-Phe2,Lys15,Arg16,Leu27)-VIP (1-7)-GRF (8-27) | 98.01% | Acetyl-(D-Phe2,Lys15,Arg16,Leu27)-VIP (1-7)-GRF (8-27) is a high-affinity, selective VPAC1 receptor antagonist, with IC50 values of 10 nM and 2000 nM for binding to human VPAC1 and VPAC2, respectively. Acetyl-(D-Phe2,Lys15,Arg16,Leu27)-VIP (1-7)-GRF (8-27) inhibits VIP-induced VPAC1/Gs/adenylate cyclase signaling with a Ki of 2 nM, and its VPAC1 selectivity is mainly determined by the N-terminal extracellular domain of the receptor. Acetyl-(D-Phe2,Lys15,Arg16,Leu27)-VIP (1-7)-GRF (8-27) can be used in studies related to VPAC1 receptor pharmacology, VIP signaling, and the structure and function of class B GPCRs. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
pTH-Related Protein (7-34) amide (human, mouse, rat) | pTH-Related Protein (7-34) amide (human, mouse, rat) is a potent antagonist of parathyroid hormone (PTH). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
